Effects of a gemcitabine plus platinum regimen combined with a dendritic cell-cytokine induced killer immunotherapy on recurrence and survival rate of non-small cell lung cancer patients

Experimental and Therapeutic Medicine

Volumn 7, Issue 5, 2014, Pages 1403-1407

  Zhao, Min ^a   Li, Hongbing ^a   Li, Lei ^a   Zhang, Yijie ^a  

^a HENAN UNIVERSITY   (China)

Author keywords

Dendritic cell cytokine induced killer cell therapy; Gemcitabine plus platinum regimen; Non small cell lung cancer; Recurrence rate; Survival rate

Indexed keywords

CISPLATIN; GEMCITABINE;

ADULT; AGED; ARTICLE; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CD3+ T LYMPHOCYTE; CD4 CD8 RATIO; CD4+ T LYMPHOCYTE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE INDUCED KILLER CELL; DENDRITIC CELL; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NATURAL KILLER CELL; SURVIVAL RATE; TREATMENT RESPONSE;

EID: 84896829817     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2014.1574     Document Type: Article

References (20)

1. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin 62: 10-29, 2012.
2. Goldstraw P, Ball D, Jett JR, Le Chevalier T, Lim E, NicholsonAG and Shepherd FA: Non-small-cell lung cancer. Lancet378: 1727-1740, 2011.
3. Naim Younes R, Gross JL, Abrao FG and Rodrigues PereiraJ: Impact of adjuvant chemotherapy in completely resected stageIIIA non-small cell lung cancer. Minerva Chir 68:169-174, 2013.
4. Filipits M and Pirker R: Predictive markers in the adjuvant therapy of non-small cell lung cancer. Lung Cancer74: 355-363, 2011.
5. Jemal A, Murray T, Ward E, etal: Cancer statistics, 2005. CACancer J Clin55: 10-30, 2005.
6. Pisters KM: Adjuvant chemotherapy for non-small-cell lung cancer-the smoke clears. N Engl J Med352: 2640-2642, 2005.
7. Ost D, Goldberg J, Rolnitzky L and Rom WN: Survival after surgery in stageIA and IB non-small cell lung cancer. AmJRespir Crit Care Med177: 516-523, 2008.
8. Zhong GC, Yan B, Sun Y, etal: Clinical efficacy of immunotherapy of dendritic cell and cytokine-induced killer cell combined with chemotherapy for treatment of multiple myeloma. Zhonghua Xue Ye Xue Za Zhi33: 1000-1003, 2012 (In Chinese).
9. Zhan HL, Gao X, Pu XY, Li W, Li ZJ, Zhou XF and QiuJG: A randomized controlled trial of postoperative tumor lysate-pulsed dendritic cells and cytokine-induced killer cells immunotherapy in patients with localized and locally advanced renal cell carcinoma. Chin Med J (Engl) 125: 3771-3777, 2012.
10. Shi SB, Ma TH, Li CH and Tang XY: Effect of maintenance therapy with dendritic cells: cytokine-induced killer cells in patients with advanced non-small cell lung cancer. Tumori 98: 314-319, 2012.
11. Sargent D, Shi Q, Yothers G, etal; Adjuvant Colon Cancer End-points (ACCENT) Group: Two or three year disease-free survival (DFS) as a primary end-point in stageIII adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07 and C89803. Eur J Cancer 47: 990-996, 2011.
12. Fidler MJ, Kim AW, Zusag T and Bonomi P: Treatment of locally advanced non-small cell lung cancer. Clin Adv Hematol Oncol7: 455-464, 479-480, 2009.
13. Juretic A, Sobat H and Samija M: Combined modality therapy of non-small cell lung cancers. Ann Oncol 10 (Suppl 6): 93-98, 1999.
14. Seder CW, Allen MS, Cassivi SD, etal: StageIIIA non-small cell lung cancer: morbidity and mortality of three distinct multimodality regimens. Ann Thorac Surg 95: 1708-1716, 2013.
15. Carney DN: Lung cancer-time to move on from chemotherapy. NEngl JMed346: 126-128, 2002.
16. -/lowcells correlate with clinical cancer stage and pathological grade in patients with bladder carcinoma. J Int Med Res 39: 1381-1391, 2011.
17. Ren J, Di L, Song G, etal: Selections of appropriate regimen of high-dose chemotherapy combined with adoptive cellular therapy with dendritic and cytokine-induced killer cells improved progression-free and overall survival in patients with metastatic breast cancer: reargument of such contentious therapeutic preferences. Clin Transl Oncol15: 780-788, 2013.
18. Shi L, Zhou Q, Wu J, Ji M, Li G, Jiang J and Wu C: Efficacy of adjuvant immunotherapy with cytokine-induced killer cells in patients with locally advanced gastric cancer. Cancer Immunol Immunother 61: 2251-2259, 2012.
19. Sangiolo D, Mesiano G, Carnevale-Schianca F, PiacibelloW, Aglietta M and Cignetti A: Cytokine induced killer cells as adoptive immunotherapy strategy to augment graft versus tumor after hematopoietic cell transplantation. Expert Opin Biol Ther 9: 831-840, 2009.
20. Zheng YW, Li RM, Zhang XW and Ren XB: Current adoptive immunotherapy in non-small cell lung cancer and potential influence of therapy outcome. Cancer Invest 31: 197-205, 2013.